JW (Cayman) Therapeutics Co. Ltd.(DE:JNY)
€0.25-0.02 (-8.03%)
DE:JNY
JW (Cayman) Therapeutics Co. Ltd. financials statements
€0.25
At close:-0.02 (-8.03%)
JW (Cayman) Therapeutics Co. Ltd. (JNY) Ratios
0 Followers
JW (Cayman) Therapeutics Co. Ltd. Ratios
DE:JNY's free cash flow for Q2 2026 was ¥-88.64M. For the 2026 fiscal year, DE:JNY's free cash flow was decreased by ¥-1.08M and operating cash flow was ¥-87.56M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.45 | 1.74 | 4.04 | 4.78 | 9.53 |
| Quick Ratio | 1.29 | 1.67 | 3.90 | 4.65 | 9.37 |
| Cash Ratio | 1.28 | 1.63 | 3.80 | 4.45 | 9.22 |
| Solvency Ratio | -1.07 | -1.00 | -1.45 | -1.74 | -2.05 |
| Operating Cash Flow Ratio | -0.19 | -0.72 | -1.51 | -1.73 | -2.82 |
| Short-Term Operating Cash Flow Coverage | -0.35 | -0.92 | -3.79 | -3.77 | -112.24 |
| Net Current Asset Value | ¥ 139.72M | ¥ 297.47M | ¥ 605.23M | ¥ 1.05B | ¥ 1.57B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.27 | 0.25 | 0.15 | 0.10 | 0.05 |
| Debt-to-Equity Ratio | 0.47 | 0.36 | 0.19 | 0.12 | 0.05 |
| Debt-to-Capital Ratio | 0.32 | 0.27 | 0.16 | 0.11 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.02 | 0.09 | 0.04 | 0.03 |
| Financial Leverage Ratio | 1.77 | 1.44 | 1.27 | 1.19 | 1.12 |
| Debt Service Coverage Ratio | -0.71 | -1.02 | -5.58 | -5.05 | -96.04 |
| Interest Coverage Ratio | -21.70 | -37.58 | -63.60 | -126.11 | -281.98 |
| Debt to Market Cap | 0.25 | 0.77 | 0.31 | 0.15 | 0.02 |
| Interest Debt Per Share | 0.66 | 1.05 | 0.80 | 0.70 | 0.37 |
| Net Debt to EBITDA | 1.51 | 0.88 | 1.05 | 1.47 | 2.28 |
| Profitability Margins | |||||
| Gross Profit Margin | 43.03% | 48.87% | 50.74% | 40.33% | 29.37% |
| EBIT Margin | -87.48% | -290.13% | -434.60% | -576.07% | -2505.82% |
| EBITDA Margin | -57.85% | -241.17% | -377.18% | -516.31% | -2398.62% |
| Operating Profit Margin | -87.48% | -290.28% | -454.17% | -587.42% | -2464.80% |
| Pretax Profit Margin | -194.68% | -373.30% | -441.74% | -580.73% | -2280.51% |
| Net Profit Margin | -195.76% | -373.30% | -441.74% | -580.73% | -2280.51% |
| Continuous Operations Profit Margin | -195.76% | -373.30% | -441.74% | -580.73% | -2280.51% |
| Net Income Per EBT | 100.56% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 222.55% | 128.60% | 97.26% | 98.86% | 92.52% |
| Return on Assets (ROA) | -54.79% | -35.15% | -35.79% | -30.31% | -22.54% |
| Return on Equity (ROE) | -97.20% | -50.52% | -45.61% | -35.94% | -25.17% |
| Return on Capital Employed (ROCE) | -40.78% | -37.79% | -41.96% | -34.50% | -26.02% |
| Return on Invested Capital (ROIC) | -29.51% | -28.86% | -39.43% | -32.50% | -25.84% |
| Return on Tangible Assets | -68.58% | -53.82% | -53.52% | -44.59% | -30.53% |
| Earnings Yield | -57.71% | -118.78% | -91.13% | -53.72% | -16.10% |
| Efficiency Ratios | |||||
| Receivables Turnover | 134.66 | 0.00 | 0.00 | 27.47 | 10.77 |
| Payables Turnover | 4.63 | 38.23 | 26.20 | 11.43 | 8.48 |
| Inventory Turnover | 2.54 | 2.59 | 2.46 | 2.17 | 0.69 |
| Fixed Asset Turnover | 1.31 | 0.58 | 0.51 | 0.37 | 0.08 |
| Asset Turnover | 0.28 | 0.09 | 0.08 | 0.05 | 0.01 |
| Working Capital Turnover Ratio | 1.06 | 0.28 | 0.18 | 0.10 | 0.01 |
| Cash Conversion Cycle | 67.74 | 131.47 | 134.30 | 149.96 | 517.78 |
| Days of Sales Outstanding | 2.71 | 0.00 | 0.00 | 13.29 | 33.90 |
| Days of Inventory Outstanding | 143.84 | 141.02 | 148.23 | 168.59 | 526.93 |
| Days of Payables Outstanding | 78.81 | 9.55 | 13.93 | 31.92 | 43.04 |
| Operating Cycle | 146.55 | 141.02 | 148.23 | 181.88 | 560.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.18 | -0.81 | -0.97 | -1.31 | -1.40 |
| Free Cash Flow Per Share | -0.19 | -0.84 | -1.00 | -1.50 | -1.59 |
| Dividend Paid and CapEx Coverage Ratio | -47.49 | -21.62 | -27.33 | -6.98 | -7.68 |
| Capital Expenditure Coverage Ratio | -47.49 | -21.62 | -27.33 | -6.98 | -7.68 |
| Operating Cash Flow Coverage Ratio | -0.29 | -0.79 | -1.25 | -1.92 | -3.82 |
| Operating Cash Flow to Sales Ratio | -0.28 | -2.11 | -2.29 | -3.68 | -18.22 |
| Free Cash Flow Yield | -8.37% | -70.16% | -49.01% | -38.95% | -14.54% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.73 | -0.84 | -1.10 | -1.86 | -6.21 |
| Price-to-Sales (P/S) Ratio | 3.39 | 3.14 | 4.85 | 10.81 | 141.65 |
| Price-to-Book (P/B) Ratio | 1.68 | 0.43 | 0.50 | 0.67 | 1.56 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -11.95 | -1.43 | -2.04 | -2.57 | -6.88 |
| Price-to-Operating Cash Flow Ratio | -12.20 | -1.49 | -2.12 | -2.93 | -7.77 |
| Price-to-Earnings Growth (PEG) Ratio | 0.19 | 0.04 | 0.12 | -0.11 | 0.07 |
| Enterprise Value Multiple | -4.36 | -0.43 | -0.24 | -0.63 | -3.62 |
| Enterprise Value | 696.77M | 162.29M | 155.61M | 470.98M | 2.68B |
| EV to EBITDA | -4.36 | -0.43 | -0.24 | -0.63 | -3.62 |
| EV to Sales | 2.52 | 1.03 | 0.90 | 3.23 | 86.86 |
| EV to Free Cash Flow | -8.88 | -0.47 | -0.38 | -0.77 | -4.22 |
| EV to Operating Cash Flow | -9.07 | -0.49 | -0.39 | -0.88 | -4.77 |
| Tangible Book Value Per Share | 0.86 | 1.42 | 2.36 | 3.56 | 4.94 |
| Shareholders’ Equity Per Share | 1.34 | 2.83 | 4.09 | 5.74 | 6.98 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.66 | 0.38 | 0.42 | 0.36 | 0.08 |
| Net Income Per Share | -1.30 | -1.43 | -1.87 | -2.06 | -1.76 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.23 | 1.29 | 1.02 | 1.01 | 0.91 |
| Research & Development to Revenue | 0.51 | 1.79 | 2.38 | 2.80 | 13.46 |
| SG&A to Revenue | 0.79 | 0.92 | 0.37 | 1.23 | 6.54 |
| Stock-Based Compensation to Revenue | 0.02 | 0.24 | 0.20 | 0.57 | 2.90 |
| Income Quality | 0.14 | 0.56 | 0.52 | 0.63 | 0.80 |
Currency in CNY

